coronavirus vaccine. Yet their speedy ascent has been unhindered by common scientific setbacks being reported by Western rivals, raising questions about how stringently they are vetting and reporting potential safety issues.The lack of clarity over the standards and safeguards used by Chinese developers is drawing concern because some of their vaccines are being distributed in China under an emergency use program before full regulatory approval.
In the US, President Donald Trump repeatedly claimed a working shot would be available there ahead of the Nov. 3 election.That hasn’t panned out as the most optimistic timelines for US emergency use authorization now go into late November and December, well behind China on this front.